Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.73 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053728 | 1.00 | HTR6 (0.73) | HTR6ALKEGFRCDK1CDK4 | |
| SCHEMBL1748377 | 1.00 | HTR6 (0.73) | HTR6ALKEGFRCDK1CDK4 | |
| SCHEMBL1748376 | 1.00 | HTR6 (0.73) | HTR6ALKEGFRCDK1CDK4 | |
| Hydrochloric Acid SCHEMBL1748672 | 0.99 | HTR6 (0.72) | HTR6ALKEGFRCDK1CDK4 | |
| Hydrochloric Acid SCHEMBL1748673 | 0.99 | HTR6 (0.72) | HTR6ALKEGFRCDK1CDK4 | |
| Hydrochloric Acid SCHEMBL1748674 | 0.99 | HTR6 (0.72) | HTR6ALKEGFRCDK1CDK4 | |
| SCHEMBL5021173 | 0.92 | HTR6 (0.61) | HTR6ALKEGFRCDK1CDK4 | |
| SCHEMBL1748333 | 0.86 | HTR6 (0.75) | HTR6ALKEGFRSUV39H2ACLY | |
| Hydrochloric Acid SCHEMBL1748461 | 0.86 | HTR6 (0.74) | HTR6ALKEGFRSUV39H2ACLY | |
| SCHEMBL1748393 | 0.85 | HTR6 (0.82) | HTR6ALKEGFRCDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | claimed |
| US-8604021-B2 | Substituted arylamine compounds and methods of treatment | BECKER OREN (IL) | 2013-12-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | HTR6 1/4885ALK 658/4885EGFR 485/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | HTR6 1/4885ALK 658/4885EGFR 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.